Search research articles
Contact Us
Filters
Showing results (81-90 of 98) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations
Manfred Kaufmann, Gunter von Minckwitz, Roy Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Response-guided neoadjuvant chemotherapy for breast cancer
Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, et al.
Breast Cancer Research and Treatment
|
February 14, 2015
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Caterina Fontanella, Bianca Lederer, Stephan Gade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Breast Cancer Research and Treatment
|
March 19, 2017
Efficacy and safety of nab-paclitaxel 125 mg/m<sup>2</sup> and nab-paclitaxel 150 mg/m<sup>2</sup> compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)
Jenny Furlanetto, Christian Jackisch, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Michael Untch, Mahdi Rezai, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
Gunter von Minckwitz, Mahdi Rezai, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
Serban Dan Costa, Sibylle Loibl, Manfred Kaufmann, et al.
Anti-Cancer Drugs
|
March 16, 2019
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)
Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2013
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Jens Huober, Peter A Fasching, Claus Hanusch, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 98) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations
Manfred Kaufmann, Gunter von Minckwitz, Roy Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Response-guided neoadjuvant chemotherapy for breast cancer
Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, et al.
Breast Cancer Research and Treatment
|
February 14, 2015
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Caterina Fontanella, Bianca Lederer, Stephan Gade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Breast Cancer Research and Treatment
|
March 19, 2017
Efficacy and safety of nab-paclitaxel 125 mg/m<sup>2</sup> and nab-paclitaxel 150 mg/m<sup>2</sup> compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)
Jenny Furlanetto, Christian Jackisch, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Michael Untch, Mahdi Rezai, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
Gunter von Minckwitz, Mahdi Rezai, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
Serban Dan Costa, Sibylle Loibl, Manfred Kaufmann, et al.
Anti-Cancer Drugs
|
March 16, 2019
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)
Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2013
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44)
Jens Huober, Peter A Fasching, Claus Hanusch, et al.
Page
of 10